Showing results (311-320 of 790) with videos related to
Sort By:
Pageof 79
Neuro-Oncology|August 31, 2022
In vivo functional characterization of EGFR variants identifies novel drivers of glioblastomaKwanha Yu, Kathleen Kong, Brittney Lozzi, et al.Biochimica Et Biophysica Acta|June 19, 2002
Lysophosphatidic acid is a bioactive mediator in ovarian cancerXianjun Fang, Michel Schummer, Muling Mao, et al.Nature Communications|February 14, 2019
Deregulated Gab2 phosphorylation mediates aberrant AKT and STAT3 signaling upon PIK3R1 loss in ovarian cancerXinran Li, Victor C Y Mak, Yuan Zhou, et al.Oncogene|April 12, 2018
BRD4 facilitates replication stress-induced DNA damage responseJingwen Zhang, Austin M Dulak, Maureen M Hattersley, et al.Cancer Research|February 3, 2006
mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates AktKathryn E O'Reilly, Fredi Rojo, Qing-Bai She, et al.Plos One|May 15, 2009
Lysophosphatidic acid-induced transcriptional profile represents serous epithelial ovarian carcinoma and worsened prognosisMandi M Murph, Wenbin Liu, Shuangxing Yu, et al.Cancer Research|April 24, 2014
Genetic and pharmacological strategies to refunctionalize the von Hippel Lindau R167Q mutant proteinZhiyong Ding, Peter German, Shanshan Bai, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 31, 2012
Biomarkers of response to Akt inhibitor MK-2206 in breast cancerTakafumi Sangai, Argun Akcakanat, Huiqin Chen, et al.Nature Communications|September 30, 2018
Systems biology approach reveals a link between mTORC1 and G2/M DNA damage checkpoint recoveryHui-Ju Hsieh, Wei Zhang, Shu-Hong Lin, et al.Gynecologic Oncology|June 25, 2003
Overexpression of kallikrein 10 in epithelial ovarian carcinomasHyun S Shvartsman, Karen H Lu, John Lee, et al.Pageof 79